









Markets
/
Stocks
/
nasdaq-hrow
/

Harrow Inc

HROW

35.380USD

0.0000.00%

Close 03/26, 16:00（ET）Quotes delayed by 15 min

79.07MMarket Cap

LossP/E TTM



Harrow Inc

35.380

0.0000.00%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Harrow Inc

Currency: USD Updated: 2026-03-26

Key Insights

Harrow Inc's fundamentals are relatively healthy, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 49 out of 157 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 68.00.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Harrow Inc's Score

Industry at a Glance

Industry Ranking

49 / 157

Overall Ranking

135 / 4546

Industry

Pharmaceuticals

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Harrow Inc Highlights

StrengthsRisks

Harrow, Inc. is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the North American market. The Company offers a comprehensive portfolio of prescription and non-prescription pharmaceutical products. It owns commercial rights to portfolios of branded ophthalmic pharmaceutical products in North America, all of which are marketed under the Harrow name. It owns and operates ImprimisRx, an ophthalmology-focused pharmaceutical-compounding business. It owns United States commercial rights to various products: IHEEZO, VEVYE, TRIESENCE, VIGAMOX, ILEVRO, FLAREX, NATACYN, ZERVIATE, BYQLOVI and others. VIGAMOX (moxifloxacin hydrochloride ophthalmic solution) 0.5%, a fluoroquinolone antibiotic eye drops for the treatment of bacterial conjunctivitis caused by susceptible strains of organisms. IHEEZO (chloroprocaine hydrochloride ophthalmic gel) 3% is a low-viscosity gel indicated for ocular surface anesthesia.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 109.15% year-on-year.

Undervalued

The company’s latest PE is -253.08, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 21.85M shares, decreasing 9.94% quarter-over-quarter.

Held by Invesco

Star Investor Invesco holds 127.88K shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.25.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

68.000

Target Price

+93.18%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-03-26

The current financial score of Harrow Inc is 8.54, ranking 51 out of 157 in the Pharmaceuticals industry. Its financial status is stable, and its operating efficiency is high. Its latest quarterly revenue reached 89.09M, representing a year-over-year increase of 33.31%, while its net profit experienced a year-over-year increase of 2.23%.

Score

Industry at a Glance

Previous score

8.54

Change



Financials

6.41

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

8.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.66

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Harrow Inc's Company Valuation

Currency: USD Updated: 2026-03-26

The current valuation score of Harrow Inc is 7.39, ranking 72 out of 157 in the Pharmaceuticals industry. Its current P/E ratio is -253.08, which is -95.67% below the recent high of -10.97 and -66.00% above the recent low of -420.12.

Score

Industry at a Glance

Previous score

7.39

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 49/157

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-03-26

The current earnings forecast score of Harrow Inc is 8.75, ranking 8 out of 157 in the Pharmaceuticals industry. The average price target is 69.00, with a high of 94.00 and a low of 59.00.

Score

Industry at a Glance

Previous score

8.75

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 8 analysts

Buy

Current Rating

68.000

Target Price

+93.18%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

174

Total

Median

Average

Company name

Ratings

Analysts

Harrow Inc

HROW

Biogen Inc

BIIB

Amgen Inc

AMGN

Eli Lilly and Co

LLY

Vertex Pharmaceuticals Inc

VRTX

Gilead Sciences Inc

GILD

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-03-26

The current price momentum score of Harrow Inc is 6.92, ranking 73 out of 157 in the Pharmaceuticals industry. Currently, the stock price is trading between the resistance level at 48.84 and the support level at 27.47, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.93

Change

-0.01

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(1)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.447

Neutral

RSI(14)

38.354

Neutral

STOCH(KDJ)(9,3,3)

64.171

Buy

ATR(14)

1.709

Low Volatility

CCI(14)

66.785

Neutral

Williams %R

41.636

Buy

TRIX(12,20)

-1.362

Sell

StochRSI(14)

80.446

Overbought

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

34.842

Buy

MA10

34.734

Buy

MA20

37.459

Sell

MA50

43.539

Sell

MA100

43.767

Sell

MA200

40.561

Sell

Institutional Confidence

Currency: USD Updated: 2026-03-26

The current institutional shareholding score of Harrow Inc is 5.00, ranking 72 out of 157 in the Pharmaceuticals industry. The latest institutional shareholding proportion is 59.00%, representing a quarter-over-quarter increase of 0.40%. The largest institutional shareholder is The Vanguard, holding a total of 1.91M shares, representing 5.14% of shares outstanding, with 1.48% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Opaleye Management Inc.

3.90M

Baum (Mark L)

2.99M

+3.47%

BlackRock Institutional Trust Company, N.A.

2.23M

-1.07%

The Vanguard Group, Inc.

Star Investors

1.86M

+0.01%

Kaufman (Daniel)

1.68M

-11.69%

Private Capital Management

Star Investors

1.86M

-4.61%

Luxor Capital Group, L.P.

307.34K

Boll (Andrew R)

811.18K

+4.29%

Geode Capital Management, L.L.C.

775.64K

-4.34%

State Street Investment Management (US)

794.28K

+2.74%

Risk Assessment

Currency: USD Updated: 2026-03-26

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Pharmaceuticals domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Harrow Inc is 5.08, ranking 76 out of 157 in the Pharmaceuticals industry. The company's beta value is 0.28. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. Harrow Inc’s latest ESG disclosure leads the Pharmaceuticals industry, indicating outstanding, compliant performance across environmental management, social responsibility, and governance, which may help mitigate overall risk.